End Stage Renal Disease Clinical Trial
Official title:
Early Feasibility Study to Evaluate the Safety and Efficacy of PAK HD in ESRD Patients
Verified date | May 2024 |
Source | Nextkidney S.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary aim of this early feasibility clinical trial is to assess the biochemical safety of dialysate regeneration with the optimised PAK HDsorbent cartridge in a limited number (n=3) of participants and treatments (one therapy per subject). As a secondary aim, we will assessthe therapy efficacy of the PAK HD sorbent therapy in short-daily hemodialysis (SDHD) and compare it to that of conventional CHD underthe same therapy settings. Following up from the preceding FIH trial, this continuation aims at demonstrating that the optimised PAK HD sorbent system has overcome previous problems of increased dialysate acidity and provides improved control over the patient's acid-base balance.
Status | Completed |
Enrollment | 3 |
Est. completion date | April 24, 2024 |
Est. primary completion date | April 24, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 79 Years |
Eligibility | Inclusion Criteria: 1. Subjects must be adults >/= 21 years old and <80 years old. 2. Subjects must be weighing >/= 55kg and <90kg (patient's dry weight). 3. Subjects must have stable haemoglobin >/= 10.5g/dL 2 months prior to enrolment 4. Subjects' pre-dialysis serum values must be within the following range, 2 months prior to enrolment: Patient allowable serum biochemistry ranges Allowable pre-dialysis serum values Na >/= 132 mmol/L or </= 145mmol/L HCO3 >/= 15mmol/L or </= 30mmol/L K >/= 3.5mmol/L or </= 5.8mmol/L 5. Subjects on stable on thrice weekly 4-h HD schedule. Stability is defined as: - Haemodynamic stability during dialysis (absence of hypotensive events and symptomatic arrhythmias), no angina pectoris, AND - No altered level of consciousness during dialysis. 6. Subjects with a well-functioning vascular access (native fistula graft): - capable of providing a blood flow rate of >/= 250 mL/min, AND - no vascular access revision and stable shunt flow for at least 4 weeks prior to enrolment. 7. Subjects capable of understanding the informed consent form and give informed consent. 8. Subjects willing and able to comply with study procedures and to attend all study follow-up visits. 9. Subjects who are female of reproducible age to practice birth control methods. 10. Subjects can be either gender. Exclusion Criteria: 1. Subjects with haemoglobin level of <10.5g/dL in any measurement 2 months prior to enrolment. 2. Subjects with the following pre-dialysis serum values in any measurement 2 months prior to enrolment: - sodium concentration <132 mmol/L or > 145mmol/L - bicarbonate <15mmol/L or >30mmol/L - plasma potassium concentration <3.5mmol/L or >5.8mmol/L - urea <15mmol/L or >28 mmol/L 3. Subjects with severe hypertension: systolic blood pressure > /=180 mmHg, diastolic blood pressure >/=120 mmHg in any officemeasurement less than 4 weeks prior to enrolment. 4. Subjects with chronic obstructive pulmonary disease or any respiratory disease that may predispose to CO2 retention. 5. Subjects with impaired liver function. Impaired liver function is defined as an elevated ALT (alanine aminotransferase) by 3-fold orgreater above the upper limit of normal. 6. Subjects with episodes of haemolysis in any measurement 3 months prior to enrolment. 7. Subjects with a central venous catheter. 8. Subjects with vascular access dysfunction (whether or not requiring an intervention), i.e. failure to achieve and/ or sustain a bloodflow of >/=250 mL/min and/or signs of compromised vascular access patency (according to the opinion of the investigator) within 4weeks prior to enrolment. 9. Subjects with vascular access related infection less than 4 weeks prior to enrolment 10. Subjects requiring an average ultrafiltration volume >2.8 L per 4-h treatment in mid-week dialysis session in the past 4 weeks priorto enrolment. 11. Subjects who are on heparin free dialysis 12. Subjects who are unable to provide informed consent. 13. Subjects who are unable to comply with study procedures. 14. Subjects with psychosocial problems which may negatively influence dialysis treatment. 15. Subjects who participated in another clinical intervention or device trial less than 12 weeks prior to enrolment, are currentlyparticipating or intend to participate in such a trial. 16. Subjects who are pregnant, breast feeding, or planning a pregnancy within the study period. 17. Subjects with a life expectancy <1 year. 18. Subjects who are anticipating a living donor kidney transplantation within < 2 months of the study period. 19. Subjects with recent history of drug and/or alcohol abuse in the last 3 months prior to enrolment. |
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital Investigational Medicine Unit | Singapore |
Lead Sponsor | Collaborator |
---|---|
Nextkidney S.A. |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary objective of this early feasibility clinical trial is to assess the (short term) clinical safety of the PAK HD sorbent treatment in a limited number of patients and treatments. | The clinical safety of the PAK HD will be evaluated in terms of the following primary endpoints:
a) Absence of serious adverse events (SAE) b) Absence of critical change in patient's clinical condition and vital parameters (Blood pressure, heart rate, body temperature and respiratory rate and pulse oximetry) during treatment. c) Absence of critical change in haematology and biochemistry immediately before the start of therapy and immediately after completion of therapy, including acid-base state, electrolytes, and ammonia. |
2 weeks | |
Secondary | The secondary objective of this study is to evaluate the efficacy of the PAK HD therapy in comparison to CHD, in terms of uremic toxin removal efficacy (urea, creatinine and phosphate). | The therapy efficacy will be evaluated with the secondary endpoint:
a) PAK HD therapy provides equivalent toxin clearances for urea, phosphate and creatinine as compared to CHD |
2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04076488 -
Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases
|
N/A | |
Completed |
NCT03289650 -
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
|
Phase 3 | |
Completed |
NCT04042324 -
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01242904 -
Use of a Bimodal Solution for Peritoneal Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03257410 -
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Withdrawn |
NCT02130817 -
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
|
Phase 4 | |
Completed |
NCT05540457 -
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Recruiting |
NCT02176434 -
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease
|
N/A | |
Active, not recruiting |
NCT02581449 -
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
|
Phase 2 | |
Completed |
NCT02832466 -
Quantifying the Deterioration of Physical Function in Renal Patients
|
N/A | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02215655 -
Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence
|
N/A | |
Completed |
NCT02830490 -
Reliability of Functional Measures in Hemodialysis Patient.
|
N/A | |
Completed |
NCT02832440 -
Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis
|
N/A | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A |